Long Term Follow-Up of Axi-Cel in R/R Non-Hodgkin Lymphoma : Sattva S. Neelapu, MD


The professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Sattva S. Neelapu, MD, professor and deputy department chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, to learn more about the long-term follow-up analysis of the phase 2 ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Updated findings from the ZUMA-5 trial, with at least 2 years of follow-up, were presented at the American Society of Hematology 2021 Meeting, December 11-14. Altogether, 149 patients were treated on the study. Among the efficacy-evaluable population (n = 110), the complete response rate was 79% in patients with follicular lymphoma and 63% in patients with marginal zone lymphoma (MZL), Neelapu explains.

After a median follow-up of 30.9 months in the follicular lymphoma cohort, 57% of patients remain in ongoing response, and the estimated median PFS was about 39.6 months, Neelapu continues. In the MZL cohort, the median follow-up was 23.8 months and 50% of the patients remain in remission, Neelapu concludes.

Related Videos
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
Frederick “Eric” Arnold, PhD
David Porter, MD
Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.